Event-Driven Stocks

Foghorn Therapeutics Inc.

FHTXNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$30.9M$22.6M$34.2M$19.2M$1.3M$430,000
Operating income−$86.4M−$102.7M−$107.9M−$117.1M−$100.7M−$68.5M
Net income−$74.3M−$86.6M−$98.4M−$108.9M−$101.3M−$68.8M
Total assets$198.1M$284.0M$285.9M$404.9M$519.8M$255.6M
Total liabilities$306.6M$329.5M$363.1M$404.8M$422.9M$109.4M
Equity−$108.5M−$45.5M−$77.2M$112,000$96.9M$146.2M
EPS (diluted)$-1.18$-1.58$-2.34$-2.62$-2.73$-6.23
Shares out.55.6M42.6M41.8M41.4M36.8M36.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−279.5%
Net margin
−240.3%
Return on equity
68.5%
Return on assets
−37.5%
Return on capital (ROCE)
−62.4%
Liabilities / assets
154.8%
Debt / equity
—
Book value / share
$-1.95
Revenue growth (YoY)
36.8%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-10.28distress
Accruals / assets
6.0%moderate
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
49
/ 100
Profitability 20Growth 100Catalyst 67Earnings quality 33Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 4 warning● 2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.3M9.6-1.2%
Apr 30, 20261.4M11.8-1.3%
Apr 15, 20261.4M10.0+3.5%
Mar 31, 20261.3M7.1+3.6%
Mar 13, 20261.3M6.5+8.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.